

Table S1. Patient characteristics by CCND1 status.

| Characteristic | Low CCND1 | | High CCND1 | |
|--|---------------|---------------|---------------|---------------|
| | # of patients | % of patients | # of patients | % of patients |
| Receptor status (p=0.14* for receptor status; p=0.01 for ER status; p=0.35 for PR status) | | | | |
| ER and/or PR positive | 294 | 73 | 33 | 87 |
| ER and PR negative | 48 | 12 | 1 | 3 |
| ER negative and PR unknown | 59 | 15 | 4 | 10 |
| ER positive | 254 | 63 | 32 | 84 |
| ER negative | 147 | 37 | 6 | 16 |
| PR positive | 165 | 41 | 12 | 32 |
| PR negative | 63 | 16 | 5 | 13 |
| PR unknown | 173 | 43 | 21 | 55 |
| Nodal status (p=0.15) | | | | |
| Node-negative | 105 | 26 | 4 | 10 |
| 1-3 nodes | 217 | 54 | 27 | 71 |
| 4-9 nodes | 69 | 17 | 6 | 16 |
| 10+ nodes | 10 | 3 | 1 | 3 |
| Adjuvant chemotherapy (p=0.29) | | | | |
| CEF | 98 | 24 | 5 | 13 |
| CMF | 175 | 44 | 19 | 50 |
| AC | 128 | 32 | 14 | 37 |
| Age (years) (p=0.64) | | | | |
| Median | 45.7 | | 45.0 | |
| Range | 29.3-57.8 | | 27.1-54.1 | |
| Stage (pathologic) (p=0.39) | | | | |
| I | 39 | 10 | 2 | 5 |

| | | | | |
|------------------------------------|-----|----|----|----|
| II | 336 | 84 | 35 | 92 |
| III | 26 | 6 | 1 | 3 |
| Pathologic T stage (p=0.67) | | | | |
| 1 | 167 | 42 | 15 | 39 |
| 2 | 204 | 51 | 22 | 58 |
| 3/4 | 30 | 7 | 1 | 3 |
| ECOG status (p=0.04) | | | | |
| 0 | 268 | 67 | 23 | 61 |
| 1 | 130 | 32 | 13 | 34 |
| 2 | 3 | 1 | 2 | 5 |
| Treatment (p=0.49) | | | | |
| Tamoxifen | 198 | 49 | 21 | 55 |
| Placebo | 203 | 51 | 17 | 45 |

* p-values refer to difference between high and low CCND1 groups by chi-square test except for age, for which a Wilcoxon two-sample test was used.